Boundless Bio, Inc.
BOLD
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.02% | 38.60% | 46.78% | 39.84% | 61.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.02% | 2.71% | 32.49% | 25.16% | 38.90% |
| Operating Income | 12.02% | -2.71% | -32.49% | -25.16% | -38.90% |
| Income Before Tax | 7.66% | -2.13% | -35.44% | -25.32% | -36.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.66% | -2.13% | -35.44% | -25.32% | -36.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.66% | -2.13% | -35.44% | -25.32% | -36.93% |
| EBIT | 12.02% | -2.71% | -32.49% | -25.16% | -38.90% |
| EBITDA | 12.45% | -2.43% | -32.72% | -25.38% | -39.38% |
| EPS Basic | 9.03% | 94.24% | 92.45% | 93.07% | 92.50% |
| Normalized Basic EPS | 9.05% | 94.24% | 92.45% | 93.07% | 92.50% |
| EPS Diluted | 9.03% | 94.24% | 92.45% | 93.07% | 92.50% |
| Normalized Diluted EPS | 9.05% | 94.24% | 92.45% | 93.07% | 92.50% |
| Average Basic Shares Outstanding | 1.51% | 1,672.66% | 1,692.76% | 1,709.27% | 1,726.12% |
| Average Diluted Shares Outstanding | 1.51% | 1,672.66% | 1,692.76% | 1,709.27% | 1,726.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |